Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-08
2009-08-18
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07576093
ABSTRACT:
The present invention relates to a new use of a compound of the formula (I)wherein R1is NH2, piperazin-1-yl, 4-methylpiperazin-1-yl,4-methyl-1,4-diazepan-1-yl or 4-ethylpiperazin-1-yl;R2is hydrogen, fluoro, CH3, CH2CH3, OCH3, CF3or OCF3;R3is hydrogen, CH3or fluoro;as a free base or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention and/or treatment of bone-related disorders, osteoporosis and increasing bone formation, bone mineral density. The present invention further relates to a method of prevention and/or treatment of these disorders.
REFERENCES:
patent: 2003/0176484 (2003-09-01), Day-Lollini et al.
patent: 2005/0054663 (2005-03-01), Bennett et al.
patent: 2006/0252045 (2006-11-01), Moitreyee et al.
patent: 0157022 (2001-08-01), None
patent: 03/004472 (2003-01-01), None
patent: 03057202 (2003-07-01), None
patent: 03076442 (2003-09-01), None
patent: 2005027883 (2005-03-01), None
patent: 2005039485 (2005-05-01), None
Johansen et al., Medline Abstract of Drugs & Aging (Feb. 1996), vol. 8, No. 2, pp. 113-125.
Frost, Medline Abstract of Medicina, (1997), vol. 57, Suppl. 1, pp. 116-126.
Boyle, Medline Abstract of Balilliere's clinical rheumatology, (Oct. 1993), vol. 7, No. 3, pp. 515-534.
Albrektsson, T., Brånemark P-I et al, “Osseointegrated Titanium Implants”, Acta Orthop. Scand. 1981, 52, pp. 155-170.
Bain, G. et al, “Activated β-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction”, Biochemical and Biophysical Research Communications 2003, 301, pp. 84-91.
Bell, N.H., “Advances in the Treatment of Osteoporosis”, Current Drug Targets—Immune, Endocrine & Metabolic Disorders, 2001, vol. 1, No. 1, pp. 93-102.
Broulik, P.D. et al, “Alterations in human serum alkaline phosphatase and its bone isoenzyme by chronic administration of lithium”, Clinica Chimica Acta, 1984, 140, pp. 151-155.
Smith, E. et al, “Glucocorticoids Inhibit Cell Cycle Progression in Differentiating Osteoblasts via Glycogen Synthase Kinase-3β”, The Journal of Biological Chemistry 2002, vol. 277, No. 20, May 17, pp. 18191-18197.
Kapadia et al, “Glycogen Synthase Kinase 3 Controls Endochondral Bone Development: Contribution of Fibroblast Growth Factor 18”, Developmental Biology, 2005; 496-507, 285.
Kulkarni et al. “Orally Bioavailable GSK3 alpha/beta Dual Inhibitor Increases Markers of Cellular Differentiation in-vitro and Bone Mass in-vivo”; Journal of Bone and Mineral Research 2006; 910-920, 21(6).
Tobias et al “Novel Therapeutic Targets in Osteoporosis”; Expert Opinion on Therapeutic Targets; 2002; 41-56, 6(1).
Skoglund et al; “Simvastatin Improves Fracture Healing in Mice”; Journal of Bone and Mineral Research; 2002; 2004-2008, 17.
Abdul et al; “Inhibiting Glycogen Synthase Kinase-3 (GSK-3) Prevents the Development of Myeloma Bone Disease”; Abstract No. 008. Cancer and Bone Society meeting in Sydney in Mar. 2009.
Brandstrom et al; “GSK-3 Inhibition Increases Trabecular Bone Mass in Mice”; American Society for Bone Mineral Research Annual Meeting; 2006; Abstract No. SA396.
Gong et al; “LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development”; Cell; 2001; 513-523, 107.
Boyden et al; “High Bone Density Due to a Mutation in LDL-Receptor-Related Protein 5”; The New England Jnl of Medicine; 2002; 1513-1521; 346(20).
Little et al; “A Mutation in the LDL Receptor-Related Protein 5 Gene Results in the Autosomal Dominant High-Bone-Mass Trait”; American Jnl of Human Genetics; 2002; 11-19, 70.
Van Wesenbeeck et al; “Six Novel Missense Mutations in the LDL Receptor-Related Protein 5 (LRP5) Gene in Different Conditions with an Increased Bone Density”; American Jnl of Human Genetics; 2003; 763-771; 72.
Bennett et al; “Regulation of Osteoblastogenesis and Bone Mass by Wnt10b”; PNAS; 2005; 3324-3329; 102(9).
Bennett et al; “Regulation of Wnt Signaling during Adipogenesis”; The Jnl of Biological Chemistry; 2002; 30998-31004; 277(34).
Gregory et al; “How Wnt Signaling Affects Bone Repair by Mesenchymal Stem Cells from the Bone Marrow”; New York Academy of Sciences; 2005; 97-106; 1049.
Ross et al; “Inhibition of Adipogenesis by Wnt Signaling”; Science; 2000; 950-953; 289.
Day et al; “Wnt/(3-Catenin Signaling in Mesenchymal Progenitors Controls Osteoblast and Chondrocyte Differentiation during Vertebrate Skeletogenesis”; Developmental Cell; 2005; 739-750; 8.
Hill et al; “Canonical Wnt/(3-Catenin Signaling Prevents Osteoblasts from Differentiating into Chondrocytes”; Developmental Cell; 2005; 727-738; 8.
Clement-Lacroix et al; “Lrp5-Independent Activation of Wnt Signaling by Lithium Chloride Increases Bone Formation and Bone Mass in Mice”; PNAS; 2005; 17406-17411; 102(48).
Tian et al; “The Role ofthe Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma”; The New England Jnl of Medicine; 2003; 2483-2494; 349(26).
Berg Anna-Lena
Bhat Ratan
AstraZeneca AB
Henley, III Raymond J
Mitchell Kenneth F.
LandOfFree
Method of treatment of bone-related disorders or conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment of bone-related disorders or conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment of bone-related disorders or conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4137539